The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regulus to Host NASDAQ Closing Bell Ceremony on December 5, 2012

Monday, December 03, 2012

Regulus to Host NASDAQ Closing Bell Ceremony on December 5, 201208:00 EST Monday, December 03, 2012LA JOLLA, Calif., Dec. 3, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it will host The NASDAQ Stock Market Closing Bell at the NASDAQ MarketSite in Times Square, New York on December 5, 2012.  Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will ring The NASDAQ Stock Market Closing Bell.  Dr. Xanthopoulos will be joined by members of Regulus' executive management team and Regulus employees to commemorate the event. Regulus began trading on the NASDAQ Global Market following the successful completion of its Initial Public Offering in October 2012.  A live webcast of the NASDAQ Closing Bell Ceremony will be available online at www.regulusrx.com and at http://www.nasdaq.com/about/marketsitetowervideo.asx.  About RegulusRegulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.For more information, please visit http://www.regulusrx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. SOURCE Regulus Therapeutics Inc.For further information: Amy Conrad, Director, Investor Relations and Corporate Communications, Regulus Therapeutics Inc., +1-858-202-6300, aconrad@regulusrx.com; David Schull, Russo Partners LLC, +1-212-845-4271, david.schull@russopartnersllc.com